Abstract
After more than a century of efforts to establish cancer immunotherapy in clinical practice, the advent of checkpoint inhibition (CPI) therapy was a critical breakthrough toward this direction (Hodi et al. in Cell Rep 13(2):412–424, 2010; Wolchok et al. in N Engl J Med 369(2):122–133, 2013; Herbst et al. in Nature 515(7528):563–567, 2014; Tumeh et al. in Nature 515(7528):568–571, 2014). Further, CPIs shifted the focus from long studied shared tumor-associated antigens to mutated ones. As cancer is caused by mutations in somatic cells, the concept to utilize these correlates of ‘foreignness’ to enable recognition and lysis of the cancer cell by T cell immunity seems an obvious thing to do.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Abelin JG et al (2017) Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity 46(2):315–326
Alexandrov LB et al (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415–421
Arnold PY et al (2002) The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues. J Immunol (Baltimore, Md.: 1950) 169(2):739–749
Baghdadi M et al (2013) Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer Immunol Immunother: CII 62(4):629–637
Balachandran VP et al (2017) Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature
Bartkowiak T et al (2015) Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci USA 112(38):E5290–E5299
Bassani-Sternberg M et al (2015) Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics: MCP 14(3):658–673
Bosch GJ et al (1996) Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88(9):3522–3527
Britten CM et al (2013) The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol 31(10):880–882
Carreno BM et al (2015) A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science (New York, N.Y.) 348(6236):803–808
Castle JC et al (2012) Exploiting the mutanome for tumor vaccination. Can Res 72(5):1081–1091
Christinck ER et al (1991) Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352(6330):67–70
Cohen AD et al (2006) Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Can Res 66(9):4904–4912
Corrales L et al (2015) Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 11(7):1018–1030
Coulie PG et al (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92(17):7976–7980
Deng L et al (2014) STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41(5):543–852
Duan F et al (2014) Genomic and bio-informatic profiling of mutational neo-epitopes reveals new rules to predict anti-cancer immunogenicity. J Exp Med 211(11):2231–2248
Foley EJ (1953) Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Can Res 13(12):835–837
Galluzzi L et al (2016) Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol, Oct 17, p.Epub ahead of print
Ganss R et al (2002) Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Can Res 62:1462–1470
Gjertsen M, Breivik J, Saeterdal I (1995) Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346(8987):1399–1400
Grosso JF et al (2007) LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Investig 117(11):3383–3392
Gubin MM et al (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515(7528):577–581
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Harndahl M et al (2012) Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur J Immunol 42(6):1405–1416
Herbst RS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567
Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 363(8):711–723
Holmgaard RB et al (2015) Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep 13(2):412–424
Hoof I et al (2009) NetMHCpan, a method for MHC class i binding prediction beyond humans. Immunogenetics 61(1):1–13
Houbiers JG et al (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 23(9):2072–2077
Iida N et al (2013) Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (New York, N.Y.) 342(6161):967–970
Iwasaki A, Medzhitov R (2015) Control of adaptive immunity by the innate immune system. Nat Immunol 16(4):343–353
Johanns TM et al (2016) Endogenous neoantigen-specific CD8 T cells identified in two glioblastoma models using a cancer immunogenomics approach. Cancer Immunol Res 4(12):1007–1015
Jørgensen KW et al (2014) NetMHCstab—predicting stability of peptide-MHC-I complexes; impacts for cytotoxic T lymphocyte epitope discovery. Immunology 141(1):18–26
Kesmir C et al (2002) Prediction of proteasome cleavage motifs by neural networks. Protein Eng 15(4):287–296
Klein G et al (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Can Res 20:1561–1572
Klug F et al (2013) Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS(+)/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy. Cancer Cell 24(5):589–602
Kreiter S et al (2015) Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520(7549):692–696
Kurts C et al (1998) Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 188(2):409–414
Landais E et al (2009) New design of MHC class II tetramers to accommodate fundamental principles of antigen presentation. J Immunol 183(12):7949–7957
Lee M et al (2014) Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharmacal Res 37(9):1234–1240
Lennerz V et al (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102(44):16013–16018
Lethe B et al (1997) MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res 7(Suppl 2):S83–S88
Linch SN et al (2016) Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. Proc Natl Acad Sci USA 113(3):E319–E327
Łuksza M et al (2017) A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature
Lurquin C et al (1989) Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58(2):293–303
Manrique SZ et al (2016) Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists. Oncotarget 7(28):42919–42942
Margulies M et al (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437(7057):376–380
Marty R et al (2017) MHC-I genotype restricts the oncogenic mutational landscape. Cell, 1–12
Matsushita H et al (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482(7385):400–404
Matsuzaki J et al (2010) Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA 107(17):7875–7880
Mcgranahan N et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, N.Y.) 351(6280):1463–1469
Mohan JF, Petzold SJ, Unanue ER (2011) Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med 208(12):2375–2383. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3256971
Moynihan KD et al (2016) Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med 22(12):1402–1410
Nathanson T et al (2016) Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade. Cancer Immunol Res, Dec 12, p.Epub ahead of print
Ott PA et al (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature
Pauken KE et al (2016) Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science (New York, N.Y.) 354(6316):1160–1165
Peters B et al (2003) Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunology (Baltimore, Md. : 1950) 171(4):1741–1749
Pfirschke C et al (2016) Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44(2):343–354
Popp MW-L, Maquat LE (2013) Organizing principles of mammalian nonsense-mediated mRNA decay. Annu Rev Genet 47:139–165
Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18(6):769–778
Rasmussen M et al (2016) Pan-specific prediction of peptide-MHC class I complex stability, a correlate of T cell immunogenicity. Journal of immunology (Baltimore, Md. : 1950) 197(4):1517–1524
Rizvi NA et al (2015) Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, N.Y.) 348(6230):124–128
Robbins PF et al (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19(6):747–752
Routy B et al (2017) Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science (New York, N.Y.) 3706(November), p.eaan3706
Sahin U et al (2017) Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547(7662):222–226
Sakuishi K et al (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207(10):2187–2194
Saric T et al (2002) An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 3(12):1169–1176
Schwanhäusser B et al (2011) Global quantification of mammalian gene expression control. Nature 473(7347):337–342
Sharma MD et al (2009) Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113(24):6102–6111
Shendure J et al (2005) Accurate multiplex polony sequencing of an evolved bacterial genome. Science (New York, N.Y.) 309(5741):1728–1732
Shukla SA et al (2015) Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nature Biotechnol 33(11):1152–1158
Sibille C et al (1990) Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide. J Exp Med 172(1):35–45
Sistigu A et al (2014) Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20(11)
Sivan A et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science (New York, N.Y.) 350(6264):1084–1089
Snyder A et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189–2199
Somasundaram R et al (2006) Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Can Res 66:3287–3293
Takaku S et al (2010) Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int J Cancer 126(7):1666–1674
Tenzer S et al (2005) Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci 62(9):1025–1037
Tumeh PC et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571
Türeci O et al (2016) Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin Cancer Res 22(8):1885–1896
Van Allen EM et al (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (New York, N.Y.) 350(6257):207–211
van der Burg SH et al (1996) Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 156(9):3308–3314
Van Rooij N et al (2013) Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31(32):e439–e442
Verdegaal EME et al (2016) Neoantigen landscape dynamics during human melanoma–T cell interactions. Nature 536(7614):91–95
Vétizou M et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science (New York, N.Y.) 350(6264):1079–1084
Vita R et al (2014) The immune epitope database (IEDB) 3.0. Nucleic Acids Res 43(D1):D405–D412
Vormehr M et al (2015) Mutanome engineered RNA immunotherapy : towards patient-centered tumor vaccination. J Immunol Res Article ID 595363:6
Vormehr M et al (2016) Mutanome directed cancer immunotherapy. Curr Opin Immunol 39:14–22
Wang RF et al (1999) Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science (New York, N.Y.) 284(5418):1351–1354
Wang S et al (2016) Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci USA 113(46):E7240–E7249
Wolchok JD et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133
Wölfel T et al (1995) A p 16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (New York, N.Y.) 269(5228):1281–1284
Woller N et al (2015) Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol Ther: The Journal of the American Society of Gene Therapy 10:1630–1640
Yadav M et al (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515(7528):572–576
Zaretsky JM et al (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375(9):819–829
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Vormehr, M., Diken, M., Türeci, Ö., Sahin, U., Kreiter, S. (2020). Personalized Neo-Epitope Vaccines for Cancer Treatment. In: Theobald, M. (eds) Current Immunotherapeutic Strategies in Cancer. Recent Results in Cancer Research, vol 214. Springer, Cham. https://doi.org/10.1007/978-3-030-23765-3_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-23765-3_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-23764-6
Online ISBN: 978-3-030-23765-3
eBook Packages: MedicineMedicine (R0)